Evidence Supports Affordable 72 Hour Non-Drug Medical Device for PONV Prevention

Pressure Right® Emetic-Management Device Provides 72-Hour Effective Prophylaxis of Postoperative Nausea and Vomiting for $12 1/2 Cents Per Hour, $2.98 Per Day. Newswise — Pressure Point, Inc., Grand Rapids, Mich. – According to research studies, surgery patients are willing to pay as much as $100 to avoid the unpleasant effects of postoperative nausea and vomiting (PONV). The current solution to the PONV problem is projected to remain at an unresolved level of at least 30 percent, according to research professionals. Many explanations have been given why PONV still exists, including lack of implementation in terms of recommended guidelines. But in point of fact, it’s because of the multifaceted chemical problems resulting from anesthesia and surgery that contribute to PONV. Additionally, the prophylactic drug combinations are not adequate enough to repel the severity occurrences of PONV successfully. It has been known that emetic symptoms can last well beyond 24 hours following surgery, despite the use of prophylactic antiemetic drug combinations.

With the emergence of Pressure Right®, a 72 hour clinically validated prophylactic non-drug device, much less PONV treatments are called for and much higher patient satisfaction outcomes are achievable.

With the submission of its clinical trial, Pressure Right® achieved 510(k) premarket notification clearance from the U S Food and Drug Administration in 2011 for its (Rx) prophylactic medical device.

Our Pressure Right® Emetic-Management Device has been clinically proven to demonstrate that there is little or no need for multiple dosing of PONV prophylaxis therapies over a 72 hour postoperative period. Its core medical application focuses on consistent 72 hour optimal results in overall PONV management satisfaction outcomes to support antiemetic drug combinations.

PONV management is the basic ingredient of patient satisfaction, which is the culmination of many factors that go into achieving PONV prevention. You start with the patient PONV assessment risk, then the type and duration of surgery and anesthesia, and finally the best prophylactic approach to reduce PONV occurrences.

If a patient is determined to have a high-risk assessment for PONV, then the probability increases for him or her to experience some degree of emetic symptoms despite the use of prophylactic antiemetics, which are recommended under current PONV clinical practice guidelines.

At $12 1/2 cents per hour or $2.98 a Day, Pressure Right® addresses the needs of at-risk PONV patients by offering extended prophylactic prevention and/or relief of emetic symptoms postoperatively.

Over the last several years, PACU nurses and anesthesiologists have been looking at other prophylactic approaches as a means of developing a better representation for PONV prevention. While guideline organizations for PONV clinical practice continue to recommend the same prophylactic drug routines, the lingering effect of PONV is still apparent. Based on the current status of PONV, it is time to change the dialogue from perception to reality to achieve and accomplish a better prognosis for PONV prevention. Firstly, the notion of looking at PONV from a relative-risk perception of considering the likelihood of a PONV outcome based on qualitative factors such as the lasting effects prophylactic receptor antagonists can be dissimilar compared to absolute-risk results.

This then begs the question: why not measure the potential incidence of PONV and the need for “rescue” antiemetic medication on an absolute-risk basis instead? The absolute-risk approach would require updated clinical trial data instead of trying to determine the risk-reward tradeoff of prophylactic antiemetic drugs from algorithm calculations.

A perfect example of current absolute risk data is demonstrated in the Pressure Right® clinical trial, which showed that the combination of ondansetron and dexamethasone alone had a much higher overall incidence of PONV compared to assumed relative-risk levels.

The actual trial results of the Ondansetron and Dexamethasone combination alone showed PONV trending higher during the 0 to 72 hour postoperative period.

PONV is generally defined as being relevant during the first 24 hours after surgery. However, this definition requires that it be expanded from 24 to 72 hours because of a phenomenon known as postoperative discharge nausea and vomiting (PDNV).

Therefore, at-risk PONV patients especially those having same-day surgical procedures, which are discharged and sent home after spending a brief stay in the post-anesthesia care unit (PACU), are prime candidates for experiencing PDNV.

The patent-pending assembly-technique of our Pressure Right® Emetic-Management, Prophylactic Wrist Strip, is designed to maximize the effects of wrist acupressure on the P6 point when applied to patients’ wrists preoperatively. Our wrist strip application allows for maximum flexibility when in use for an extended period of time.

The clinical advantages of Pressure Right® in the prevention of PONV and PDNV is that it provides a broad spectrum of prophylactic efficacy throughout the 72 hour postoperative period. It tackles the effects of both early and late stage PONV and follow-on PDNV and has proven to enhance combination prophylactic therapy.

Research professionals are now concluding that the prevention prognosis for PONV under the current prophylactic drug guidelines alone has not evolved enough to truly affect the imbedded problems of PONV. Researchers have advocated the added use of effective non-pharmacological prophylactic practices, such as acupressure, which has been clinically proven to enhance patient satisfaction in PONV management.

To quote Anna Lee, PhD, a noted specialist in acupuncture and acupressure, associated with the Cochrane Library, she said, “Generally physicians and patients are not aware of the P6 stimulation type of treatment for preventing postoperative nausea and vomiting.”

Because of the Pressure Right® assembly-technique of its wrist strip, it permits the adhesive strip to remain on the skin, while promoting a blend of pressure to the P6 point that creates a prophylactic effect for broad treatment of PONV.

The reality is that Pressure Right® has the prophylactic capacity to materially improve the current PONV environment, which surgery patients would gladly pay $100 to avoid.

The prophylactic combination therapy of Pressure Right® and routine antiemetics were enhanced considerably for managing PONV in high-risk surgical populations. The 72 hour assessment period following surgery confirmed that patients were found to be in a better state of equilibrium as it related to PONV/PDNV prevention.

To find out more about our effective prophylactic intervention tool, please contact us to discuss how Pressure Right® may be of clinical value to your patients.

Please click on image link for full size version.

Contact Information:Joseph DiLustroChairman & CEOPressure Point Inc.(908) 601-8877

Website: www.pressurerightstrip.com

Email: [email protected]